James Flynn

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

Hey LinkedIn Fam - Help out Narwhal Bio! As part of the BioTools Innovator competition, Narwhal has put out a 1 min video about what we're building. The video will be part of a number of factors the BTI team of of advisors will use to rank the companies. Please go to Youtube and "Like" the video as exposure counts! https://lnkd.in/gc6zFqGf Please also "Like" this post below to keep it at the top of people's feeds! Thanks everyone!

53

1 Comment

📣 TODAY at #BPIEast: Join Oren Beske, PhD, ATUM's Amalgamator of Business & Biology, at 12:15pm to learn how you can leverage multiple orthogonal transposases in the genetic engineering of CHO cells. Then stop by Booth #831 to learn how ATUM's services and platforms can increase your productivity, effortlessly! #BPIconf #CellLineDevelopment #Biologics

13

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

43

Expert Network Spotlight Series: Join us in welcoming Ray Chui, PhD, DSP, and Joel Baublits, MS, to Endpoint Preclinical! As co-founders of Cardiovascular Analytics, Ray and Joel bring extensive expertise in cardiovascular and respiratory data analytics, biostatistics, safety pharmacology, and toxicology studies. Together, they deliver precise data analysis, GLP-compliant reporting, and comprehensive study support, ensuring that clients receive actionable insights for both regulatory submissions and product development. ------------------------------- About Ray: https://lnkd.in/gUtqtTFQ Cardiovascular & Respiratory Data Analytics - Over two decades of experience analyzing hemodynamic, ECG, and respiratory data for GLP and non-GLP studies. - Expert in platforms like EMKA ecgAUTO and DSI Ponemah, offering in-depth insights into cardiovascular and respiratory assessments. GLP Compliance & Safety Pharmacology - Extensive background in GLP compliance, quality control, and computer system validation for data collection and analysis. - Provides safety pharmacology and toxicology analysis to support both regulatory submissions and product development. Regulatory-Focused & Timely Reporting - Known for comprehensive, regulatory-compliant reports delivered on time. - Focuses on ensuring data precision and adherence to GLP guidelines for seamless regulatory review and approval. ------------------------------- About Joel: https://lnkd.in/g93Fgyb7 Biostatistics & Multimodal Data Analysis - Specializes in integrating complex cardiovascular, respiratory, and toxicology datasets to produce clear, statistically sound insights. - Skilled in using advanced statistical methods and software like SAS, R, and Prism to support robust data analysis and reporting. Respiratory & Toxicology Expertise - Provides detailed analysis and interpretation of respiratory and toxicological outcomes for both acute and chronic studies. - Ensures comprehensive, accurate reporting tailored to client needs and regulatory standards. Collaborative Approach & Study Support - Works closely with clients to design preclinical studies, ensuring protocols meet regulatory requirements and study goals. - Passionate about delivering timely, high-quality data that drives impactful decision-making. ------------------------------- Core Services - Biostatistics & Data Analysis - Report Generation - GLP Compliance & Regulatory Support - Preclinical Study Design - Training & Mentorship Contact us today to plan your next project with Ray & Joel! #Biostatistics #SafetyPharmacology #Toxicology #CardiovascularResearch #RespiratoryStudies #PreclinicalResearch #RegulatoryCompliance #GLPCompliance #CRO #Pharma #Biotech #MedicalDevices #Nonclinical #DrugDiscovery

50

7 Comments

In our most recent editorial piece, explore how Collaborative Drug Discovery (CDD)'s AI-powered search tool provides a swift and secure method for uncovering and refining potential drug candidates to boost the drug discovery process. #AI #drugdiscovery

1

🔍 Join our facilitator Alexander Ivliev at his Roundtable Discussion at the AI in Drug Discovery Xchange 2024, Boston! 🧪 📚 Dive deep into the realm of target discovery with our esteemed facilitator, Alexander Ivliev, Director of Computational Biology at Ikena Oncology. In this interactive roundtable discussion, we will brainstorm the vital components essential for a robust target discovery engine and unravel the mystery of how to integrate them effectively. ⌚ Time: 15:40 – 16:40 📅 Date: 20th June 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 🪧 Join us today & claim your COMPLIMENTARY pass today! 🪧 https://bit.ly/43qUJXC ✨ Session Highlights ✨ 🔵 The balance between in-house experimentation and leveraging public resources in target identification. 🔵 Exploring the most informative experimental approaches and data types. 🔵 Navigating approaches tailored for efficacy versus safety. 🔵 Strategies for managing the trade-off between target novelty and confidence level. 🔵 Piecing together the components into a cohesive framework. 🗣️ Alexander brings a wealth of expertise to the table, with a master’s and PhD in Bioinformatics and over a decade of experience in the field. Having spearheaded bioinformatics initiatives at Clarivate Analytics, supporting diverse clients in pharmaceutical and biotech sectors, Alexander now leads the computational biology domain at Ikena Oncology. His role is pivotal in accelerating the development of small-molecule inhibitors for cancer treatment. Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 * Agenda subject to change #TargetDiscovery #DrugDiscovery #Bioinformatics #AIinHealthcare #AIinDrugDiscovery #InnovationInMedicine #RoundtableDiscussion #Biotech #Pharmaceuticals #DataDrivenDiscovery #ExperimentalApproaches #EfficacyVsSafety #NovelTargets #ConfidenceInDiscovery #InHouseExperimentation #PublicResources #CollaborativeScience #ScientificAdvancements #BiomedicalResearch #PrecisionMedicine #FutureOfMedicine #StrategicThinking #BioinformaticsInsights #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

5

🧬 We're reaching new heights in minimal residual disease detection. Introducing MRDVision – a breakthrough in MRD combining our WGS cancer profiling platform, CancerVision, and Ultima Genomics's ppmSeq technology to deliver unmatched precision of circulating tumor DNA at an affordable cost. MRDVision sets a new standard in MRD testing by scanning the whole genome for dramatically improved precision, detecting cancer cells remaining in the body after treatment at an extremely low limit of detection (LOD) down to one-in-a-million. Read more about this exciting step as we pioneer the future of cancer genomics and precision medicine: https://lnkd.in/eHNU3sVz #MRD #minimalresidualdisease #cancergenomics #inocras #ultimagenomics

85

Illumina’s GRAIL Saga Resolution Final Resolution in Illumina's GRAIL Saga: Implications for the Industry The long-standing saga between Illumina and GRAIL has reached a resolution. This case has significant implications for market access professionals, particularly in terms of regulatory hurdles and the integration of advanced genomic technologies into mainstream healthcare. Read more about the case. How do you think this resolution will impact genomic medicine and market access? Share your thoughts! https://lnkd.in/dVAkw_zm

3

Bristol Myers Squibb pays $110M to form T-cell therapy pact, helping Prime Medicine, Inc. buy time to advance prioritized pipeline Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, which could receive a whopping $3.5 billion in milestones, disclosed the deal alongside details of a pipeline prioritization intended to extend its cash runway into the first half of 2026. BMS is partnering with Prime to further its work to unlock the potential of cell therapy in immunology and oncology. In return for the upfront payment, which is split evenly between a cash payment and equity investment, Prime will design optimized Prime Editor reagents for a select number of targets. The project includes reagents that use Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology. https://lnkd.in/e2Zi36Kk

89

🔬 At 4Cell Therapies, we harness the power of CAR-T technology to revolutionize cancer treatment. This cutting-edge approach aligns with our mission to deliver innovative and personalized therapies for patients with difficult-to-treat cancers. Here's how CAR-T therapy works: 1. T Cell Collection: T cells are isolated from the patient's blood. 2. Genetic Modification: T cells are modified to recognize cancer cells. 3. Cell Expansion: The modified T cells are grown in large numbers. 4. Patient Infusion: T cells are infused back into the patient to target and destroy cancer. Why is CAR-T Revolutionary? Precise Action: Targets only cancer cells. Long-lasting Response: One dose can lead to long-term remission. Personalized Treatment: Tailored therapy for each patient. By investing in CAR-T technology, we aim to bring hope to many patients with hard-to-treat cancers. At 4Cell Therapies, we're committed to advancing this technology to unlock its full potential for transformative cancer care. #Immunotherapy #CART #Oncology #MedicalInnovation #Biotechnology #Cancer

11

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer ➤ Phase III ALINA study showed alectinib reduced the risk of disease recurrence or death by 76% (HR=0.24, 95% CI: 0.13-0.43, p<0.0001) vs. platinum-based chemotherapy in people with completely resected IB (tumor ≥ 4 cm) to IIIA ALK-positive NSCLC. ➤ In an exploratory analysis, an improvement of central nervous system (CNS)-DFS was observed (HR=0.22; 95% CI: 0.08-0.58). ➤ Review utilized RTOR and Project Orbis (FDA w/Australia’s TGA, Health Canada, Israel’s MoH, Swissmedic & the UK’s MHRA). Brazil's ANVISA and Singapore’s HAS will also be participating as Type C Project Orbis Partners. https://lnkd.in/eJnA_2M3

3

1 Comment

Exciting advancements in proteomics! Aimee Cichocki explores how AI is revolutionizing predictive mass spectra analysis, enabling more precise peptide identification and enhancing our understanding of health and disease. Deep learning models like Prosit and innovative tools from companies like MSAID and Talus Bio are driving this transformative change. Don't miss out on this groundbreaking article! 🔗 Discover more: https://lnkd.in/eYw7ViYb #AIinScience #Proteomics #DeepLearning #ArtificialIntelligence

7

#LanternPharma announced a strategic AI-driven collaboration with #OregonTherapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. https://shorturl.at/alnoZ #TechNews #StayInformed #StayAhead #dailydose #followus #staytuned #stayconnected #technews #technology #trending #trendingnow #trendingnews #explore #explorepage #techdogs

4

🌟 Exploring the Future of Autoimmune Disease Treatment 🌟 Read our recent blog post to learn all about the future of cell therapies in treating autoimmune conditions: https://lnkd.in/g-sAw5mW ​

2